Dima is the founding and managing partner of 4BIO Capital, a London-based investment firm focused exclusively on advanced therapies. At 4BIO, he leads the team of physicians and scientists responsible for sourcing, evaluation, and post-investment management of both private and public investments. He is responsible for shaping and maintaining the firm’s proprietary technology strategy, the in-house research efforts, and academic collaborations. He oversees more than $100 million in investment funds for venture creation and academic entrepreneurship in advanced therapies.

Prior to founding 4BIO, he has spent many years in academia, focusing successively on structural biology, neurochemistry, systems neuroscience, brain-computer interfaces, and gene therapy. I contributed to the foundation of the field of chemogenetics (control of excitable cells using a combination of gene therapy and small molecules). Several academic projects Dr Kuzmin contributed to are now advancing towards clinical trials. He served on the boards of several pioneering advanced therapies companies, including Retrosense (acquired by Allergan), Redpin Therapeutics (acquired by Kriya), Araris Biotech, Code Biotherapeutics, and Ray Therapeutics.

Dima’s passion is to deliver outright cures for chronic diseases. Beside his work as the managing partner of 4BIO, he is an Assistant Professor of Medicine (Adjunct) at Yale University. He is a Kauffman Fellow (Class 26), and a Fellow of the Royal Society of Biology (2021) as well as the Royal Society of Medicine (2022). Outside of work, he enjoys free-ride skiing, sailing, fencing, jazz music, and poetry.